Nostrum Laboratories and its founder and CEO, Nirmal Mulye, PhD, agreed to pay between $3.8 million and $50 million to settle allegations of underpaying Medicaid rebates.
Read the full post on Becker's Hospital Review - Healthcare News
Drugmaker, CEO agree to pay up to $50M in false claims suit
